Skip to main content
Erschienen in: Inflammopharmacology 2/2018

04.08.2017 | Original Article

Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis

verfasst von: Felipe Grabarz, Cristhiane Favero Aguiar, Matheus Correa-Costa, Tárcio Teodoro Braga, Meire I. Hyane, Vinícius Andrade-Oliveira, Maristella Almeida Landgraf, Niels Olsen Saraiva Câmara

Erschienen in: Inflammopharmacology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary fibrosis is a result of an abnormal wound healing in lung tissue triggered by an excessive accumulation of extracellular matrix proteins, loss of tissue elasticity, and debit of ventilatory function. NKT cells are a major source of Th1 and Th2 cytokines and may be crucial in the polarization of M1/M2 macrophages in pulmonary fibrogenesis. Although there appears to be constant scientific progress in that field, pulmonary fibrosis still exhibits no current cure. From these facts, we hypothesized that NKT cells could influence the development of pulmonary fibrosis via modulation of macrophage activation. Wild type (WT) and NKT type I cell-deficient mice (Jα18−/−) were subjected to the protocol of bleomycin-induced pulmonary fibrosis with or without treatment with NKT cell agonists α-galactosylceramide and sulfatide. The participation of different cell populations, collagen deposition, and protein levels of different cytokines involved in inflammation and fibrosis was evaluated. The results indicate a benign role of NKT cells in Jα18−/− mice and in wild-type α-galactosylceramide–sulfatide-treated groups. These animals presented lower levels of collagen deposition, fibrogenic molecules such as TGF-β and vimentin and improved survival rates. In contrast, WT mice developed a Th2-driven response augmenting IL-4, 5, and 13 protein synthesis and increased collagen deposition. Furthermore, the arginase-1 metabolic pathway was downregulated in wild-type NKT-activated and knockout mice indicating lower activity of M2 macrophages in lung tissue. Hence, our data suggest that NKT cells play a protective role in this experimental model by down modulating the Th2 milieu, inhibiting M2 polarization and finally preventing fibrosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Allen JE, Sutherland TE (2014) Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin. Semin Immunol 26:329–340CrossRefPubMedPubMedCentral Allen JE, Sutherland TE (2014) Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin. Semin Immunol 26:329–340CrossRefPubMedPubMedCentral
Zurück zum Zitat American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 161:646–664CrossRef American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 161:646–664CrossRef
Zurück zum Zitat Burdin N, Brossay L, Kronenberg M (1999) Immunization with alpha-galactosylceramide polarizes CD1-reactive NKT cells towards Th2 cytokine synthesis. Eur J Immunol 29:2014–2025CrossRefPubMed Burdin N, Brossay L, Kronenberg M (1999) Immunization with alpha-galactosylceramide polarizes CD1-reactive NKT cells towards Th2 cytokine synthesis. Eur J Immunol 29:2014–2025CrossRefPubMed
Zurück zum Zitat Chua F, Gauldie J, Laurent GJ (2005) Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 33:9–13CrossRefPubMed Chua F, Gauldie J, Laurent GJ (2005) Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 33:9–13CrossRefPubMed
Zurück zum Zitat Coker RK, Laurent GJ (1998) Pulmonary fibrosis: cytokines in the balance. Eur Respir J 11:1218–1221CrossRefPubMed Coker RK, Laurent GJ (1998) Pulmonary fibrosis: cytokines in the balance. Eur Respir J 11:1218–1221CrossRefPubMed
Zurück zum Zitat Gharaee-Kermani M, McGarry B, Lukacs N et al (1998) The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol 64:657–666CrossRefPubMed Gharaee-Kermani M, McGarry B, Lukacs N et al (1998) The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol 64:657–666CrossRefPubMed
Zurück zum Zitat Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604CrossRefPubMed Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604CrossRefPubMed
Zurück zum Zitat Kim JH, Kim HY, Kim S et al (2005) Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. Am J Pathol 167:1231–1241CrossRefPubMedPubMedCentral Kim JH, Kim HY, Kim S et al (2005) Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. Am J Pathol 167:1231–1241CrossRefPubMedPubMedCentral
Zurück zum Zitat Kimura T, Ishii Y, Morishima Y et al (2004) Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol 172:5782–5789CrossRefPubMed Kimura T, Ishii Y, Morishima Y et al (2004) Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol 172:5782–5789CrossRefPubMed
Zurück zum Zitat Miyamoto K, Miyake S, Yamamura T (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531–534. doi:10.1038/35097097 CrossRefPubMed Miyamoto K, Miyake S, Yamamura T (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531–534. doi:10.​1038/​35097097 CrossRefPubMed
Zurück zum Zitat Murray LA, Rosada R, Moreira AP et al (2010) Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. doi:10.1371/journal.pone.0009683 Murray LA, Rosada R, Moreira AP et al (2010) Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. doi:10.​1371/​journal.​pone.​0009683
Zurück zum Zitat Nadas J, Li C, Wang PG (2009) Computational structure activity relationship studies on the CD1d/glycolipid/TCR complex using AMBER and AUTODOCK. J Chem Inf Model 49:410–423. doi:10.1021/ci8002705 CrossRefPubMed Nadas J, Li C, Wang PG (2009) Computational structure activity relationship studies on the CD1d/glycolipid/TCR complex using AMBER and AUTODOCK. J Chem Inf Model 49:410–423. doi:10.​1021/​ci8002705 CrossRefPubMed
Zurück zum Zitat Strieter RM, Keane MP (2004) Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest 114:165–168CrossRefPubMedPubMedCentral Strieter RM, Keane MP (2004) Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest 114:165–168CrossRefPubMedPubMedCentral
Zurück zum Zitat Van Kaer L, Parekh VV, Wu L (2011) Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res 343:43–55CrossRefPubMed Van Kaer L, Parekh VV, Wu L (2011) Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res 343:43–55CrossRefPubMed
Zurück zum Zitat Zhang K, Gharaee-Kermani M, McGarry B, Phan SH (1994) In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection. Lab Invest 70:192–202PubMed Zhang K, Gharaee-Kermani M, McGarry B, Phan SH (1994) In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection. Lab Invest 70:192–202PubMed
Metadaten
Titel
Protective role of NKT cells and macrophage M2-driven phenotype in bleomycin-induced pulmonary fibrosis
verfasst von
Felipe Grabarz
Cristhiane Favero Aguiar
Matheus Correa-Costa
Tárcio Teodoro Braga
Meire I. Hyane
Vinícius Andrade-Oliveira
Maristella Almeida Landgraf
Niels Olsen Saraiva Câmara
Publikationsdatum
04.08.2017
Verlag
Springer International Publishing
Erschienen in
Inflammopharmacology / Ausgabe 2/2018
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-017-0383-7

Weitere Artikel der Ausgabe 2/2018

Inflammopharmacology 2/2018 Zur Ausgabe